{"status": "OK", "response": {"docs": [{"type_of_material": "News", "blog": [], "news_desk": "Business", "lead_paragraph": "The industry\u2019s lobbying effort could blunt new competition to its products and reduce the savings anticipated in the federal health care overhaul.", "headline": {"main": "Biotech Firms,\r\nBillions at Risk,\r\nLobby States to\r\nLimit Generics", "print_headline": "Battle in States On Generic Copies Of Biotech Drugs"}, "abstract": "Some of nation\u2019s biggest biotechnology companies are lobbying in statehouses nationwide to limit generic competition to their blockbuster drugs; drugmakers Amgen and Genentech are proposing bills that would restrict ability of pharmacists to substitute generic versions for brand name products; say such measures are needed to protect patient safety.", "print_page": "1", "word_count": "1237", "_id": "5107846600315214fbb87a0b", "snippet": "The industry\u2019s lobbying effort could blunt new competition to its products and reduce the savings anticipated in the federal health care overhaul.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2013/01/29/business/battle-in-states-on-generic-copies-of-biotech-drugs.html", "multimedia": [{"subtype": "wide", "url": "images/2013/01/29/business/Drug/Drug-thumbWide.jpg", "height": 126, "width": 190, "legacy": {"wide": "images/2013/01/29/business/Drug/Drug-thumbWide.jpg", "wideheight": "126", "widewidth": "190"}, "type": "image"}, {"subtype": "xlarge", "url": "images/2013/01/29/business/Drug/Drug-articleLarge.jpg", "height": 1000, "width": 600, "legacy": {"xlargewidth": "600", "xlarge": "images/2013/01/29/business/Drug/Drug-articleLarge.jpg", "xlargeheight": "1000"}, "type": "image"}, {"subtype": "thumbnail", "url": "images/2013/01/29/business/Drug/Drug-thumbStandard.jpg", "height": 75, "width": 75, "legacy": {"thumbnailheight": "75", "thumbnail": "images/2013/01/29/business/Drug/Drug-thumbStandard.jpg", "thumbnailwidth": "75"}, "type": "image"}], "subsection_name": null, "keywords": [{"value": "Drugs (Pharmaceuticals)", "is_major": "Y", "rank": "1", "name": "subject"}, {"value": "Biotechnology", "is_major": "N", "rank": "2", "name": "subject"}, {"value": "Law and Legislation", "is_major": "N", "rank": "3", "name": "subject"}, {"value": "Generic Brands and Products", "is_major": "Y", "rank": "4", "name": "subject"}, {"value": "Inventions and Patents", "is_major": "N", "rank": "5", "name": "subject"}, {"value": "Genentech Inc", "is_major": "Y", "rank": "6", "name": "organizations"}, {"value": "Amgen Inc", "is_major": "Y", "rank": "7", "name": "organizations"}, {"value": "Patient Protection and Affordable Care Act (2010)", "is_major": "N", "rank": "8", "name": "subject"}, {"value": "States (US)", "is_major": "Y", "rank": "9", "name": "subject"}, {"value": "Lobbying and Lobbyists", "is_major": "Y", "rank": "10", "name": "subject"}], "byline": {"contributor": "", "person": [{"organization": "", "role": "reported", "rank": 1, "firstname": "Andrew", "lastname": "POLLACK"}], "original": "By ANDREW POLLACK"}, "document_type": "article", "pub_date": "2013-01-29T00:00:00Z", "section_name": "Business Day"}], "meta": {"hits": 1, "offset": 0, "time": 32}}, "copyright": "Copyright (c) 2013 The New York Times Company.  All Rights Reserved."}